Cargando…

Adaptive therapy achieves long-term control of chemotherapy resistance in high grade ovarian cancer

Drug resistance results in poor outcomes for most patients with metastatic cancer. Adaptive Therapy (AT) proposes to address this by exploiting presumed fitness costs incurred by drug-resistant cells when drug is absent, and prescribing dose reductions to allow fitter, sensitive cells to re-grow and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hockings, Helen, Lakatos, Eszter, Huang, Weini, Mossner, Maximilian, Khan, Mohammed Ateeb, Metcalf, Stephen, Nicolini, Francesco, Smith, Kane, Baker, Ann-Marie, Graham, Trevor A., Lockley, Michelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401956/ https://www.ncbi.nlm.nih.gov/pubmed/37546942 http://dx.doi.org/10.1101/2023.07.21.549688

Ejemplares similares

LiquidCNA: Tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations
por: Lakatos, Eszter, et al.
Publicado: (2021)

Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer
por: Silva, Vera L., et al.
Publicado: (2021)

The role of single-cell sequencing in studying tumour evolution
por: Mossner, Maximilian, et al.
Publicado: (2021)

A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
por: Newton, C., et al.
Publicado: (2019)

The role of PARP inhibitor combination therapy in ovarian cancer
por: Hockings, Helen, et al.
Publicado: (2023)

The peritoneal tumour microenvironment of high-grade serous ovarian cancer
por: Leinster, D Andrew, et al.
Publicado: (2012)

The role of MET in chemotherapy resistance
por: Wood, Georgina E., et al.
Publicado: (2021)

First passage time analysis of spatial mutation patterns reveals sub-clonal evolutionary dynamics in colorectal cancer
por: Haughey, Magnus J., et al.
Publicado: (2023)

The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
por: Cheng, Zhao, et al.
Publicado: (2022)

Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of oesophagael adenocarcinoma
por: Barroux, Melissa, et al.
Publicado: (2023)

Carvedilol targets β-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy
por: Hoare, Joseph I., et al.
Publicado: (2022)

Achievements of Cancer Chemotherapy
por: Tobias, J. S., et al.
Publicado: (1976)

NeoPredPipe: high-throughput neoantigen prediction and recognition potential pipeline
por: Schenck, Ryan O., et al.
Publicado: (2019)

The mutational signatures of formalin fixation on the human genome
por: Guo, Qingli, et al.
Publicado: (2022)

STAT1‐associated intratumoural T(H)1 immunity predicts chemotherapy resistance in high‐grade serous ovarian cancer
por: Au, Katrina K, et al.
Publicado: (2016)

Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer
por: Vanguri, Rami, et al.
Publicado: (2022)

Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer
por: Crispin-Ortuzar, Mireia, et al.
Publicado: (2023)

Principles of dormancy evident in high-grade serous ovarian cancer
por: Shepherd, Trevor G., et al.
Publicado: (2022)

Body Composition and Metabolic Dysfunction Really Matter for the Achievement of Better Outcomes in High-Grade Serous Ovarian Cancer
por: Cuello, Mauricio A., et al.
Publicado: (2023)

Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
por: Marchocki, Zibi, et al.
Publicado: (2022)

Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer
por: Deen, Surrin S., et al.
Publicado: (2019)

Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
por: Rundo, Leonardo, et al.
Publicado: (2022)

Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer
por: Lee, Yong Jae, et al.
Publicado: (2022)

Identification of Ovarian Cancer Patients Most Likely to Achieve Chemotherapy Response Score 3 Following Neoadjuvant Chemotherapy: Development of a Predictive Nomogram
por: Liang, Wei-feng, et al.
Publicado: (2020)

Establishing grading indices of available soil potassium on paddy soils in Hubei province, China
por: Li, Xiaokun, et al.
Publicado: (2018)

Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease
por: Santoro, Angela, et al.
Publicado: (2019)

Elastography, a sensitive tool for the evaluation of neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma
por: XIE, MENG, et al.
Publicado: (2014)

A chemotherapy response classifier based on support vector machines for high-grade serous ovarian carcinoma
por: Sun, Chao-Yang, et al.
Publicado: (2015)

Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
por: Han, Chanhee, et al.
Publicado: (2018)

Targeting Microtubule-Associated Protein Tau in Chemotherapy-Resistant Models of High-Grade Serous Ovarian Carcinoma
por: Barbolina, Maria V.
Publicado: (2022)

A case of primary ovarian lymphoma with autoimmune hemolytic anemia achieving complete response with Rituximab-based combination chemotherapy
por: Ghadyalpatil, N. S., et al.
Publicado: (2011)

Chemotherapy for high-grade gliomas
por: Galanis, E, et al.
Publicado: (2000)

STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer
por: Ghaffari, Abdi, et al.
Publicado: (2018)

Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first‐line platinum chemotherapy in high grade serous ovarian cancer
por: Weberpals, Johanne I., et al.
Publicado: (2021)

Retinoblastoma: Achieving new standards with methods of chemotherapy
por: Kaliki, Swathi, et al.
Publicado: (2015)

Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation
por: Terzic, Julie, et al.
Publicado: (2020)

The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction
por: Johnson, Racheal Louise, et al.
Publicado: (2021)

The co-evolution of the genome and epigenome in colorectal cancer
por: Heide, Timon, et al.
Publicado: (2022)

Social and Emotional Learning and Ninth-Grade Students’ Academic Achievement
por: Atkins, Jessica L., et al.
Publicado: (2023)

Epigenetic Therapy Augments Classic Chemotherapy in Suppressing the Growth of 3D High-Grade Serous Ovarian Cancer Spheroids over an Extended Period of Time
por: Bilbao, Michelle, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9h4vhooufh8mnunqhfu5rj778r